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Purpose: The forced mid-expiratory flow (FEF25-75%) value is a potentially sensitive marker 
of obstructive peripheral airflow. We aimed to assess whether FEF25-75% can be an early 
predictor of chronic obstructive pulmonary disease (COPD).
Patients and Methods: Between July 1, 2007 and June 31, 2009, we identified 3624 
patients who underwent a pulmonary function test (PFT) in Gangnam Severance Hospital. 
We selected 307 patients aged over 40 years without COPD who had normal PFT results at 
baseline and who had follow-up PFT records more than 1 year later. A FEF25-75% z-score less 
than −0.8435 was considered low. We defined COPD as a forced expiratory volume in 
one second/forced vital capacity value of less than 0.7 before July 31, 2019.
Results: Among 307 patients, 91 (29.6%) had low FEF25-75% at baseline. After 10 years, the 
incidence rate of COPD in the low FEF25-75% group was significantly higher than that in the normal 
FEF25-75% group (41.8% vs 7.4%; P-value<0.001). The Cox proportional hazard model showed that 
age (hazard ratio [HR] 1.09; P-value<0.001), smoking status (occasional smoker HR, 4.59; P- 
value<0.001 and long-term smoker HR, 2.18; P-value=0.023), and low FEF25-75% (HR, 3.31; P- 
value<0.001) were predictive factors for the development of COPD.
Conclusion: The FEF25-75% value in patients with normal lung function is a useful predictor 
for the development of COPD. We should carefully monitor patients who present with low 
FEF25-75% values, even if they have normal lung function.
Keywords: COPD, respiratory function tests, tobacco
Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic 
airway disease;1 however, the economic burden of terminal COPD is enormous, with 
COPD being a leading cause of death worldwide. Accurate prediction and early detection 
of COPD may encourage patients to stop smoking and allow for appropriately timed 
treatments.2 Ultimately, the ability to predict COPD may prevent airway remodeling, 
improve prognosis, and diminish its medical and economic burden.3,4 Many researchers 
have attempted to identify early predictors for COPD development. The pulmonary 
function test (PFT) is a safe and practical procedure that is widely performed to detect 
COPD. Recently, a decrease in the forced expiratory volume in one second (FEV1)5 or 
diffusing capacity of the lungs for carbon monoxide (DLCO)6 in PFT has been suggested 
as a marker to predict COPD development (FEV1/forced vital capacity [FVC] <0.7). In 
the clinic, we frequently encounter patients who smoke, have respiratory symptoms, and 
have normal PFT results. We hypothesized that among some patients with normal lung 
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function, including normal FEV1 and DLCO values, forced 
mid-expiratory flow (FEF25-75%) may be an early predictive 
marker for the development of COPD among high-risk 
individuals.
FEF25-75% is the most sensitive measure of airflow in 
peripheral airways where primary airflow obstruction 
originates,7 and it is reduced in early bronchial impairment, 
which is associated with small airway disease.8–11 Airway 
remodeling, mucus plugging, and immune cell infiltration 
induced by cigarette smoking ultimately result in small airway 
disease, which is a cardinal feature of COPD.12 Some research-
ers have found that decreased FEF25-75% is frequently observed 
in patients with COPD.13 We can therefore assume that 
FEF25-75% might be an earlier marker for COPD than other 
markers, such as FEV1, DLCO, and FVC. However, no pro-
spective study has examined FEF25-75% as a predictor of 
COPD.
Thus, in this observational cohort study, we aimed to 
determine whether the FEF25-75% value measured at base-
line can predict COPD development over 10 years.
Materials and Methods
Patients and Study Flow
From July 1, 2007 to June 31, 2009, we identified 6624 patients 
who underwent PFT at Gangnam Severance Hospital. We 
excluded 4458 patients with abnormal PFT results, defined as 
at least one of the following three criteria: the FEV1/FVC 
[<0.7], FVC [<80% of predicted value], and FEV1 [<80% of 
predicted value]. An additional 1859 patients were excluded 
for the following reasons: no records of PFT performed more 
than 1 year after the baseline (n=1297), under 40 years of age 
(n=156), restrictive lung disease history (n=137), and history 
of asthma (n=125) and COPD (n=144). Finally, we reviewed 
the electronic medical records of the remaining 307 patients 
with normal PFT results at baseline and grouped them accord-
ing to the FEF25-75% values (Figure 1).
Parameters
We collected clinical information on sex, age, body mass index 
(BMI), smoking history, and the following comorbidities: 
arterial hypertension, diabetes mellitus, coronary heart disease 
(CHD), old cerebrovascular accident (CVA), alcoholics, reflux 
esophagitis (RE), peptic ulcer disease (PUD), gastroesopha-
geal reflux disease (GERD), depression, and history of pul-
monary tuberculosis. These co-morbidities were checked 
through electronic medical records. BMI was calculated by 
dividing the weight in kilograms by the square of height in 
meters (kg/m2) when the first spirometry was performed. 
Smoking status was classified as never smoked, occasional 
smoker (<20 pack-years), or long-term smoker (≥20 pack- 
years), in accordance with a previous study.14 We calculated 
pack-years by multiplying the number of packs of cigarettes 
smoked per day by the number of years the person smoked. 
This retrospective study was approved by the Institutional 
Review Board (IRB) of Gangnam Severance Hospital (num-
ber: 2019–0556-001). The requirement of informed consent 
was waived because of the retrospective nature of the study.
PFT
Baseline spirometry tests were performed during the cohort 
period using Vmax229 and Vmax22 spirometers 
(SensorMedics Corp., Italia). The procedures were performed 
following the American Thoracic Society and European 
Respiratory Society criteria, 2005,15 with all patients seated 
and wearing nose clips. The procedure was repeated three 
times, which is an acceptable and reproducible method of 
effort. When a suitable spirometry test was performed, the 
FEV1 and FVC values were determined to be the most sig-
nificant values on the FEV curves, and the two values could be 
determined on different curves. Baseline FEV1, FEV1/FVC, 
FVC, and FEF25-75% values were obtained for the study. All of 
the reference values were based on the Global Lung Function 
Initiative 2012.16
COPD Development
Patients underwent follow-up PFTs at intervals between 6 
months and 1 year. While not on a standard schedule, most 
patients in this study underwent PFTs frequently. Reasons 
for follow-up PFTs differed among patients and were as 
follows: routine follow-up, respiratory symptoms, abnor-
mal lesion in chest images, patient’s request, and doctor’s 
recommendation. If an obstructive pattern was shown in 
the PFT, a bronchodilator test was performed to evaluate 
the reversibility of bronchial obstruction.
We reviewed all PFT results, which were conducted before 
July 13, 2019. We defined the development of COPD when 
post-bronchodilation FEV1/FVC was less than 0.7.
Statistical Analysis
All analyses were performed using R Statistical Package (ver-
sion 4.0.2; Institute for Statistics and Mathematics, Vienna, 
Austria). The values are expressed as means ± standard devia-
tions for continuous variables and as numbers and percentages 
for categorical variables. FEF25-75% z-score was treated as 
both a continuous and categorical dependent variable in the 
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analyses. We used t-tests for continuous variables and chi- 
square tests for categorical variables to evaluate the relation-
ship between the outcome and independent variables. 
Univariate and multivariate Cox proportional hazards models 
were used to analyze factors associated with COPD develop-
ment. In the univariate analysis, independent variables with 
a P-value <0.05 were statistically significant and were 
included in the multivariate model. Cox proportional hazard 
analysis was used to identify differences in the cumulative 
development of COPD (%) between the normal FEF25-75% and 
low FEF25-75% groups.
Results
Baseline Clinical Characteristics of 
Enrolled Patients According to the 
Groups and the Optimal Cut-off Value for 
Low FEF25-75%
To classify patients with normal PFT results into low and 
normal FEF25-75% groups, we initially estimated the optimal 
cut-off value of FEF25-75% z-score for predicting COPD 
development using the Youden index method.17 The opti-
mal cut-off value for FEF25-75% z-score was −0.8435 
Figure 1 Flow chart of this study. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEF, forced mid-expiratory flow; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
PFT, pulmonary function test.
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(sensitivity 0.7037 and specificity 0.7905). Among 307 
patients, 216 (70.4%) and 91 (29.6%) patients were 
included in the normal FEF25-75% and low FEF25-75% 
groups, respectively (Table 1). The baseline clinical char-
acteristics, including BMI, presence of co-morbidity, his-
tory of pulmonary tuberculosis, and smoking status were 
not significantly different between the two groups. 
However, males were more predominant in the low 
FEF25-75% group than in the normal FEF25-75% group 
(73.6% vs 36.1%, P<0.001). In addition, mean patient age 
was lower in the low FEF25-75% group than in the normal 
FEF25-75% group (58.9±10.1 vs 62.5±10.5, P=0.006). 
Regarding co-morbidities, depression was more prevalent 
in the low FEF25-75% group than in the normal FEF25-75% 
group (12.1% vs 1.9%, P<0.001) (Table 1).
Baseline Pulmonary Function According 
to the Groups
When comparing baseline PFT results between the normal 
and low groups, FEV1, FEV1/FVC, and FVC values in the 
low FEF25-75% group were all significantly lower than 
those in the normal FEF25-75% group (Table 2). However, 
all PFT results were within the normal range at baseline.
Significant Predictive Factors for the 
Development of COPD
Over the 10-year follow-up, 54 patients (17.6%) developed 
COPD among 307 patients. The incidence of COPD in the low 
FEF25-75% group was significantly higher than that in the 
normal FEF25-75% group (38 patients, 41.8% vs 16 patients, 
7.4%; P<0.001). We identified significant factors for the devel-
opment of COPD using Cox proportional hazard analysis. In 
the univariate analysis, age, depression, smoking status, FEV1, 
FEV1/FVC, and FEF25-75% z-scores were significant factors in 
COPD development (Table 3). We selected significant factors 
in the univariate analysis and included them in the multivariate 
analysis. However, the variance inflation factor of FEV1 
z-scores was 6.390 in the multivariate analysis model, and it 
was not analyzed owing to multi-collinearity with other vari-
ables. The multivariate analysis revealed that the significant 
factors for COPD development were age (HR, 1.088; 95% 
confidence interval [CI], 1.050–1.128), smoking status (occa-
sional smoker HR, 4.586; 95% CI, 1.913–10.993 and long- 
term smoker HR, 2.179; 95% CI, 1.115–4.258), FEV1/FVC 
z-score (HR, 0.452; 95% CI, 0.219–0.936), and FEF25-75% 
Table 1 Baseline Characteristics of Enrolled Patients According 
to FEF25-75% z-Score






Male 145 (47.2%) 78 (36.1%) 67 (73.6%) <0.001
Mean age (years) 61.4±10.5 62.5±10.5 58.9±10.1 0.006
Height (cm) 160.7±8.7 161.0±9.0 160.2±8.0 0.486
Weight (kg) 62.2±9.4 62.6±9.7 61.2±8.8 0.231
BMI (kg/m2) 24.0±3.0 24.1±3.0 23.8±3.0 0.535
Co-morbidity
Hypertension 126 (41.0%) 87 (40.3%) 39 (42.9%) 0.770
Diabetes 57 (18.6%) 39 (18.1%) 18 (19.8%) 0.846
CHD 26 (8.5%) 19 (8.8%) 7 (7.7%) 0.926
Previous CVA 11 (3.6%) 8 (3.7%) 3 (3.3%) 1.000
RE, PUD or 
GERD
18 (5.9%) 11 (5.1%) 7 (7.7%) 0.536
Depression 15 (4.9%) 4 (1.9%) 11 (12.1%) <0.001
History of 
tuberculosis
54 (17.6%) 33 (15.3%) 21 (23.1%) 0.140
Smoking status** 0.851
Never smoker 197 (66.8%) 142 (65.7%) 55 (60.4%)
Occasional 
smoker
24 (8.1%) 16 (7.4%) 8 (8.8%)
Long-term 
smoker
74 (25.1%) 50 (23.1%) 24 (26.4%)
Unknown 12 (3.9%) 8 (3.7%) 4 (4.4%)
Notes: Data are presented as mean ± standard deviation or number of patients 
(%). *Low FEF25-75%: FEF25-75% z-score below −0.8435 (the optimal cut-off value for 
predicting COPD development). **Occasional smoker: an adult who has smoked 
less than 20 pack-years in his or her lifetime; long term smoker: an adult who has 
smoked over 20 pack-years in his or her lifetime. 
Abbreviations: BMI, body mass index; CHD, coronary heart disease; CVA, cere-
brovascular accident; FEF, forced mid-expiratory flow; GERD, gastroesophageal 
reflex disease; PUD, peptic ulcer disease; RE, reflux esophagitis.
Table 2 Results of Lung Function Test According to the 
FEF25-75% z-Score
























FEV1/FVC 77.1±4.8 78.6±4.7 73.6±2.9 <0.001
Notes: *Low FEF25-75%: FEF25-75% z-score below −0.8435 (the optimal cut-off value 
for predicting COPD development) 
Abbreviations: FEF, forced mid-expiratory flow; FEV1, forced expiratory volume 
in 1 second; FVC, forced vital capacity.
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z-score (HR, 0.453; 95% CI, 0.267–0.766). However, depres-
sion was not a significant factor for the development of COPD 
in the multivariate analysis (HR, 1.550; 95% CI, 0.674–3.566) 
(Table 3).
The low FEF25-75% group was also a significant risk 
factor for the development of COPD in the multivariate 
analysis (HR, 3.308; 95% CI, 1.650–6.632). In the Kaplan- 
Meier curve, the cumulative development of COPD was 
significantly higher in the low FEF25-75% group than in the 
normal FEF25-75% group (Figure 2; P<0.001).
Comparison of PFT Parameters for 
Predicting COPD Development
We obtained and compared the receiver operating character-
istic (ROC) curve of each PFT parameter for predicting COPD 
development (Figure 3). The area under the ROC curve was 
the highest for FEF25-75% z-score (0.779; 95% CI, 0.715–-
0.843) and FEV1/FVC z-score (0.783; 95% CI, 0.716–0.851), 
followed by FEV1 z-score (0.649; 95% CI, 0.578–0.720) and 
FVC z-score (0.557; 95% CI, 0.480–0.634).
Discussion
In this 10-year follow-up observational cohort study, we 
showed that patients with decreased FEF25-75% were sus-
ceptible to develop COPD, despite the fact that they 
showed normal lung function, including normal FEV1 
and FVC values. FEF25-75% was an independent risk factor 
for COPD even after adjustment for age, smoking history, 
and FEV1/FVC at baseline. As far as we know, this is the 
first study to reveal a significant association between 
FEF25-75% and the development of COPD. Small airway 
obstruction is a fundamental feature of COPD, and 
FEF25-75% reflects small airway disease.18 However, ear-
lier research studies have described that FEF25-75% has 
high variability, and thus, its normal range is large.19 
Therefore, FEF25-75% has not been studied for medical 
Table 3 Significant Factors for Development of COPD
Univariate Analysis Multivariate Analysis
HR 95% CI P-value HR 95% CI P-value VIF
Low FEF25-75%* † 5.665 3.156–10.166 <0.001 3.308 1.650–6.632 <0.001
Sex (male) 1.616 0.941–2.777 0.082
Age (years) 1.038 1.009–1.068 0.009 1.088 1.050–1.128 <0.001 1.254
BMI (kg/m2) 0.927 0.844–1.017 0.108
Co-morbidity
Hypertension 1.668 0.975–2.856 0.062
Diabetes 1.504 0.817–2.770 0.190
CHD 1.077 0.387–2.993 0.887
Previous CVA 1.088 0.264–4.489 0.907
RE, PUD, or GERD 1.074 0.385–2.993 0.892
Depression 2.979 1.337–6.639 0.008 1.550 0.674–3.566 0.302 1.057
History of tuberculosis 1.063 0.564–2.001 0.850
Smoking status**
(reference: never smoked)
Occasional smoker 2.242 0.968–5.195 0.060 4.586 1.913–10.993 <0.001 1.166
Long-term smoker 2.003 1.118–3.586 0.020 2.179 1.115–4.258 0.023 1.379
PFT
FEV1 z-score 0.743 0.620–0.890 0.001
FVC z-score 0.875 0.743–1.030 0.109
FEV1/FVC z-score 0.284 0.182–0.444 <0.001 0.452 0.219–0.936 0.033 2.034
FEF25-75% z-score 0.366 0.256–0.523 <0.001 0.453 0.267–0.766 0.003 1.882
Notes: †Adjusted for age, depression, smoking status, and FEV1/FVC z-score. *Low FEF25-75%: FEF25-75% z-score below −0.8435 (the optimal cut-off value for predicting COPD 
development). **Occasional smoker: an adult who has smoked less than 20 pack-years in his or her lifetime; long-term smoker: an adult who has smoked over 20 pack-years in his or her 
lifetime. 
Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; CVA, cerebrovascular accident; FEF, forced mid-expiratory flow; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; GERD, gastroesophageal reflex disease; HR, hazard ratio; PFT, pulmonary function test; PUD, peptic ulcer disease; 
RE, reflux esophagitis; VIF, variance inflation factor.
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use. Although FEF25-75% might have poor repeatability 
based on earlier studies, the predictive power of 
FEF25-75% for COPD development can cover a large vari-
able range of FEF25-75%. In this study, to reduce the 
variability of FEF25-75%, we analyzed the z-score by 
calibrating the age, sex, height, and race of each patient. 
The predictability and HR of FEF25-75% for COPD devel-
opment were equivalent to those of FEV1/FVC, the para-
meter used in the diagnostic definition of COPD.
FEF25-75% measures airway flow rates on an FVC seg-
ment, which describes the flow from medium-to-small 
airways. The impairment of FEF25-75% indicates the 
impairment of medium-sized and small airways.20 
Compromised FEF25-75% is frequently observed in patients 
with bronchial hyper-responsiveness in asthma or allergic 
rhinitis.21 Children with allergic rhinitis/asthma and 
decreased FEF25-75% have elevated values of fractional 
exhaled nitric oxide.22 Impairment of FEF25-75% is 
a marker of early bronchial impairment in allergic rhinitis 
and bronchiolitis obliterans.8,9 However, the superiority of 
FEF25-75% over FEV1/FVC has not been demonstrated in 
regard to sensitivity.23 In COPD, FEF25-75% is decreased in 
smokers compared to healthy individuals.24 Moreover, 
FEF25-75% is decreased in individuals exposed to second- 
hand smoke11 or those with air trapping observed on chest 
computed tomography.25 However, the role of FEF25-75% 
as a predictor for the development of COPD has not been 
well studied. Instead, several studies have investigated the 
parameters associated with FEF25-75% and obstructive 
disease.20 Although objective criteria for analysis are lack-
ing, the concavity of the flow-volume curve is often used 
for classifying the obstructive pattern of patients.20 
Figure 2 Differences in cumulative development of COPD (%) between normal FEF25-75% and low FEF25-75% groups. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEF, forced mid-expiratory flow.
Figure 3 Comparison of AUC of ROC curves. 
Abbreviations: AUC, area under the curve; FEF, forced mid-expiratory flow; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ROC, 
receiver operating characteristic.
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Recently, the global concavity index (100*[reference 
FEF50%–measured FEF50%]/reference FEF50%) and 
peripheral concavity index ([reference FEF75%-measured 
FEF75%]/reference FEF75%) were reported to be related 
to obstructive disease.26 However, further research is 
required.
COPD is a chronic airway disease induced by extended 
exposure to toxic particles, including components of cigar-
ettes. The small airways that are exposed to toxic materials 
chronically demonstrate marked remodeling with thick-
ened airway wall.27 This remodeling is caused by wound 
healing in response to injury by toxic materials, including 
cigarette smoking, viruses, and bacteria. Airway remodel-
ing includes wall thickness of airway, increased density of 
inflammatory cells, fibrosis, and smooth muscle hyperpla-
sia. Mucus plugs, which are a significant feature of COPD, 
also lead to small airway dysfunction.12 Immune cell infil-
tration induced by smoking precedes fibrosis of small air-
ways and loss of lung tissue.28 These above mechanisms 
might identify subclinical COPD patients with small air-
way dysfunction before the impairment of lung function 
and may reveal impairment of FEF25-75% in advance.
We found that old age and smoking status were signifi-
cant predictors for the development of COPD in this study. 
Age and smoking history are well-known critical factors for 
COPD.1 We demonstrated that well-known factors for the 
development of COPD are statistically significant in our 
sample. FEV1 is a well-known marker for airway obstruction 
and is used to measure severity of airway obstruction and can 
predict mortality.29 In our univariate analysis, FEV1 was 
significant. However, it showed multi-collinearity with 
FEF25-75% and FEV1/FVC and was therefore not included 
in the multivariate analysis model. We speculated that com-
pared to FEV1, FEF25-75% is a better predictor for the devel-
opment of COPD in the comparison of ROC in patients with 
normal lung function. We can therefore assume that 
FEF25-75% can be an earlier marker for COPD than FEV1.
Early diagnosis and prediction of COPD are essential 
for improving the prognosis of COPD patients.1 We can 
identify patients susceptible to the development of COPD 
and provide interventions to prevent COPD. Furthermore, 
we should recommend patients with decreased FEF25-75% 
to quit smoking and educate them about lifestyle issues, 
including avoiding dust, appropriate vaccinations, regular 
exercise, and nutritional support, even when they do not 
have symptoms or show reduced lung function.27 Early 
intervention, management, and close monitoring will help 
prevent the progression of COPD. Regular follow-up of 
patients can detect COPD in the early stage, leading to 
improved treatment timing, prevention of airway remodel-
ing, and improvement of severity and prognosis.
This study had some limitations. First, this study was 
conducted at a single institute with a limited number of 
patients. In this respect, the optimal cut-off value of 
FEF25-75% used in this study cannot be generalized. 
Therefore, further large-scale studies are needed. 
However, we had sufficient patients to obtain significant 
results of well-known risk factors, including age and 
smoking history. Second, the FEF25-75% value is known 
to have considerable variability, and the normal range 
was shown to be quite broad in earlier studies. However, 
previous studies also reported that FEF25-75% is rela-
tively reliable when FVC and FEV1 are normal.29 We 
included patients with normal FVC and FEV1, specifi-
cally to evaluate FEF25-75%. In addition, because all 
values were calibrated as the z-score, we could reduce 
the variability of FEF25-75%. Third, we included patients 
that were assessed with two different types of spirom-
eters, resulting in potential systematic differences 
between lung function measurements.30 Finally, the 
interval between PFTs varied. In Korea, the national 
health insurance covers almost all Koreans, allowing 
patients to use medical services frequently and quickly. 
Thus, frequent PFTs are usually conducted. Most of our 
study patients underwent PFT at a 6-month to 1-year 
interval. We think this varied interval of PFT is not 
a major problem that would weaken the power of the 
results of the present study.
Conclusions
This retrospective, observational cohort study revealed 
that the FEF25-75% value in patients with normal lung 
function can be useful in predicting the development of 
COPD. We should thus carefully monitor patients who 
present with low FEF25-75% values who are susceptible to 
COPD, even though they may have normal lung function. 
Early interventions in these patients, including smoking 
cessation, timed vaccinations, sufficient exercise, and 
environmental care, may help improve their prognosis.
Abbreviations
BMI, body mass index; CHD, coronary heart disease; COPD, 
chronic obstructive pulmonary disease; CVA, cerebrovascular 
accident; DLCO, diffusing capacity of the lungs for carbon 
monoxide; FEF25-75%, forced mid-expiratory flow25-75%; 
FEV1, forced expiratory volume in one second; FVC, forced 
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vital capacity; GERD, gastroesophageal reflux disease; HR, 
hazard ratio; PFT, pulmonary function test; PUD, peptic ulcer 
disease; RE, reflux esophagitis.
Data Sharing Statement
The datasets used and/or analyzed during the current study are 
available from the corresponding author on reasonable 
request.
Ethics Approval
Institutional Review Board (IRB) of Gangnam Severance 
Hospital (number: 2019-0556-001).
Consent for Publication
The requirement of informed consent was waived because of 
the retrospective nature of the study, and all data were col-
lected in accordance with the amended Declaration of 
Helsinki.
Funding
There is no funding to report.
Disclosure
The authors declare that they have no competing interests.
References
1. Park YB, Rhee CK, Yoon HK, et al. Revised (2018) COPD clinical 
practice guideline of the korean academy of tuberculosis and respira-
tory disease: a summary. Tuberc Respir Dis (Seoul). 2018;81 
(4):261–273. doi:10.4046/trd.2018.0029
2. Devine JF. Chronic obstructive pulmonary disease: an overview. Am 
Health Drug Benefits. 2008;1(7):34–42.
3. Csikesz NG, Gartman EJ. New developments in the assessment of 
COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis. 
2014;9:277–286.
4. Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment 
to slow disease progression. Int J Clin Pract. 2015;69(3):336–349. 
doi:10.1111/ijcp.12522
5. Park HJ, Byun MK, Rhee CK, Kim K, Kim HJ, Yoo KH. Significant 
predictors of medically diagnosed chronic obstructive pulmonary disease 
in patients with preserved ratio impaired spirometry: a 3-year cohort study. 
Respir Res. 2018;19(1):185. doi:10.1186/s12931-018-0896-7
6. Harvey BG, Strulovici-Barel Y, Kaner RJ, et al. Risk of COPD with 
obstruction in active smokers with normal spirometry and reduced 
diffusion capacity. Eur Respir J. 2015;46(6):1589–1597. doi:10.1183/ 
13993003.02377-2014
7. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for 
lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/ 
09031936.05.00035205
8. Ciprandi G, Cirillo I, Klersy C, et al. Role of FEF25-75 as an early marker of 
bronchial impairment in patients with seasonal allergic rhinitis. Am J Rhinol. 
2006;20(6):641–647. doi:10.2500/ajr.2006.20.2914
9. Patterson GM, Wilson S, Whang JL, et al. Physiologic definitions of 
obliterative bronchiolitis in heart-lung and double lung transplanta-
tion: a comparison of the forced expiratory flow between 25% and 
75% of the forced vital capacity and forced expiratory volume in one 
second. J Heart Lung Transplant. 1996;15(2):175–181.
10. Malerba M, Radaeli A, Olivini A, et al. Association of fef25-75% 
impairment with bronchial hyperresponsiveness and airway inflam-
mation in subjects with asthma-like symptoms. Respiration. 2016;91 
(3):206–214. doi:10.1159/000443797
11. Bird Y, Staines-Orozco H. Pulmonary effects of active smoking and 
secondhand smoke exposure among adolescent students in Juarez, 
Mexico. Int J Chron Obstruct Pulmon Dis. 2016;11:1459–1467. 
doi:10.2147/COPD.S102999
12. Higham A, Quinn AM, Cancado JED, Singh D. The pathology of small 
airways disease in COPD: historical aspects and future directions. 
Respir Res. 2019;20(1):49. doi:10.1186/s12931-019-1017-y
13. Williamson PA, Clearie K, Menzies D, Vaidyanathan S, Lipworth BJ. 
Assessment of small-airways disease using alveolar nitric oxide and 
impulse oscillometry in asthma and COPD. Lung. 2011;189 
(2):121–129. doi:10.1007/s00408-010-9275-y
14. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER. Do 
symptoms predict COPD in smokers? Chest. 2010;137(6):1345–1353.
15. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of 
spirometry. European Respiratory J. 2005;26(2):319. doi:10.1183/ 
09031936.05.00034805
16. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference 
values for spirometry for the 3-95-yr age range: the global lung 
function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. 
doi:10.1183/09031936.00080312
17. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3 
(1):32–35. doi:10.1002/1097-0142(1950)3:1<32::AID- 
CNCR2820030106>3.0.CO;2-3
18. Deepak D, Prasad A, Atwal SS, Agarwal K. Recognition of small 
airways obstruction in asthma and COPD the road less travelled. 
J Clin Diagnostic Res. 2017;11(3):TE01–TE05.
19. Lung function testing: selection of reference values and interpretative 
strategies. American thoracic society. Am Rev Respir Dis. 1991;144 
(5):1202–1218.
20. Hoesterey D, Das N, Janssens W, et al. Spirometric indices of early 
airflow impairment in individuals at risk of developing COPD: spiro-
metry beyond FEV1/FVC. Respir Med. 2019;156:58–68. 
doi:10.1016/j.rmed.2019.08.004
21. Ciprandi G, Cirillo I. Forced expiratory flow between 25% and 75% 
of vital capacity may be a marker of bronchial impairment in allergic 
rhinitis. J Allergy Clin Immunol. 2011;127(2):549; discussion 
550–541. doi:10.1016/j.jaci.2010.10.053
22. Ciprandi G, Tosca MA, Cirillo I, et al. Impaired FEF25-75 may 
predict high exhaled nitric oxide values in children with allergic 
rhinitis and/or asthma. J Biol Regul Homeost Agents. 2012;26(1 
Suppl):S27–33.
23. Lebecque P, Kiakulanda P, Coates AL. Spirometry in the asthmatic 
child: is FEF25-75 a more sensitive test than FEV1/FVC? Pediatr 
Pulmonol. 1993;16(1):19–22. doi:10.1002/ppul.1950160105
24. Kornmann O, Beeh KM, Beier J, et al. Newly diagnosed chronic 
obstructive pulmonary disease. Clinical features and distribution of 
the novel stages of the global initiative for obstructive lung disease. 
Respiration. 2003;70(1):67–75. doi:10.1159/000068417
25. Lee SM, Seo JB, Lee SM, Kim N, Oh SY, Oh YM. Optimal threshold 
of subtraction method for quantification of air-trapping on coregis-
tered CT in COPD patients. Eur Radiol. 2016;26(7):2184–2192. 
doi:10.1007/s00330-015-4070-z
26. Johns DP, Walters JAE, Walters EH. Diagnosis and early detection of 
COPD using spirometry. J Thorac Dis. 2014;6(11):1557–1569.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                            
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 2920
Kwon et al                                                                                                                                                            Dovepress
27. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway 
obstruction in chronic obstructive pulmonary disease. N Engl J Med. 
2004;350(26):2645–2653. doi:10.1056/NEJMoa032158
28. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in 
the peripheral airways of young cigarette smokers. N Engl 
J Med. 1974;291(15):755–758. doi:10.1056/NEJM1974101 
02911503
29. Sin DD, Wu L, Man SF. The relationship between reduced lung 
function and cardiovascular mortality: a population-based study and 
a systematic review of the literature. Chest. 2005;127(6):1952–1959. 
doi:10.1378/chest.127.6.1952
30. Milanzi EB, Koppelman GH, Oldenwening M, et al. Considerations in 
the use of different spirometers in epidemiological studies. 
Environmental Health. 2019;18(1):39. doi:10.1186/s12940-019-0478-2
International Journal of Chronic Obstructive Pulmonary Disease                                                       Dovepress 
Publish your work in this journal 
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is 
given to the pathophysiological processes underlying the disease, inter-
vention programs, patient focused education, and self management 
protocols. This journal is indexed on PubMed Central, MedLine 
and CAS. The manuscript management system is completely online 
and includes a very quick and fair peer-review system, which is 
all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.  
Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
International Journal of Chronic Obstructive Pulmonary Disease 2020:15                                          submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2921
Dovepress                                                                                                                                                           Kwon et al
